TY - JOUR
T1 - Ethnicity and ERG frequency in prostate cancer
AU - Sedarsky, Jason
AU - Degon, Michael
AU - Srivastava, Shiv
AU - Dobi, Albert
N1 - Publisher Copyright:
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Emerging observations emphasize a distinct biology of prostate cancer among men of different ethnicities and races, as demonstrated by remarkable differences in the frequency of ERG oncogenic activation, one of the most common and widely studied prostate cancer driver genes. Worldwide assessment of ERG alterations frequencies show consistent trends, with men of European ancestry having the highest rates of alteration and men of African or Asian ancestries having considerably lower alteration rates. However, data must be interpreted cautiously, owing to variations in assay platforms and specimen types, as well as ethnic and geographical classifications. Many opportunities and challenges remain in assessing cancer-associated molecular alterations at a global level, and these need to be addressed in order to realize the true potential of precision medicine for all cancer patients.
AB - Emerging observations emphasize a distinct biology of prostate cancer among men of different ethnicities and races, as demonstrated by remarkable differences in the frequency of ERG oncogenic activation, one of the most common and widely studied prostate cancer driver genes. Worldwide assessment of ERG alterations frequencies show consistent trends, with men of European ancestry having the highest rates of alteration and men of African or Asian ancestries having considerably lower alteration rates. However, data must be interpreted cautiously, owing to variations in assay platforms and specimen types, as well as ethnic and geographical classifications. Many opportunities and challenges remain in assessing cancer-associated molecular alterations at a global level, and these need to be addressed in order to realize the true potential of precision medicine for all cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=85041643431&partnerID=8YFLogxK
U2 - 10.1038/nrurol.2017.140
DO - 10.1038/nrurol.2017.140
M3 - Review article
C2 - 28872154
AN - SCOPUS:85041643431
SN - 1759-4812
VL - 15
SP - 125
EP - 131
JO - Nature Reviews Urology
JF - Nature Reviews Urology
IS - 2
ER -